PDF: Update on Drugs & Devices: September – October 2022

PDF Download: Update covering: Roflumilast cream 0.3% (Zoryve™), Ruxolitinib cream 1.5% (Opzelura™), HA-based dermal filler (Juvéderm® Volux™ XC), Abrocitinib tablets (Cinbinqo®), LetibotulinumtoxinA for injection (Letybo®), Berotralstat capsules (Orladeyo®), Mogamulizumab IV infusion (Poteligeo®), and Avacopan capsules (Tavneos®).